Abdollah Assad, MD
Geriatric Psychiatry · Reno, NVNPI 1588633143
Payments from drug & device makers
Across 234 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$940
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$922
- Takeda Pharmaceuticals U.S.A., Inc.$414
- Otsuka America Pharmaceutical, Inc.$383
- Teva Pharmaceuticals USA, Inc.$350
- Vanda Pharmaceuticals Inc.$228
- plus $756 from 11 others
What the payments were for
- Food & beverage$3,85697%
- Education$1353%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $940 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $922 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $414 |
| Otsuka America Pharmaceutical, Inc. | 19 | $383 |
| Teva Pharmaceuticals USA, Inc. | 15 | $350 |
| Vanda Pharmaceuticals Inc. | 14 | $228 |
| Corium, LLC | 9 | $141 |
| Alkermes, Inc. | 5 | $119 |
| Johnson & Johnson | 5 | $118 |
| Eisai Inc. | 5 | $93 |
| Lundbeck LLC | 4 | $67 |
| Almatica Pharma LLC | 3 | $61 |
| Adlon Therapeutics L.p. | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Shire North American Group Inc | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
Too few geriatric psychiatry providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 29 | $63,673 |
| RexultiBrexpiprazole | 21 | $32,362 |
| AdderallDextroamphetamine/Amphetamine | 12 | $3,812 |
| Olanzapine | 83 | $3,447 |
| Ziprasidone Hcl | 40 | $3,446 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 150 | $3,100 |
| Lamotrigine | 139 | $2,677 |
| Quetiapine Fumarate | 90 | $2,302 |
| Clozapine | 17 | $1,974 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 22 | $1,493 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 47 | $977 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $962 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 70 | $947 |
| Hydroxyzine Pamoate | 44 | $887 |
| Buprenorphine Hcl | 82 | $799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $940 | $63,67329 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $383 | $32,36221 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Adderall | $414 | $3,81212 claims |
| Almatica Pharma LLCSertraline Hcl | $61 | $8612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric psychiatry providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other geriatric psychiatry in Reno
- Clare Bajamundi-PlylerReno$172
- Luis Carlos OrtegaLas Vegas$6K
- Hisbay AliLas Vegas$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.